In 1855, Abraham Lincoln wrote a letter to his best friend, Joshua Speed. Speed was from a wealthy, slave-owning Kentucky family; Lincoln believed slavery was wrong. You are mistaken about this, Lincoln wrote to Speed. But, differ we must."
One way for Lincoln to have dealt with his best friend, I suppose, would be to say you're a horrible person, you're morally wrong, and I shun you," says NPR's Steve Inskeep. "Lincoln did not take that approach, which I think might be a little controversial today."
You might know Steve primarily for hosting NPR's Morning Edition. He also writes histories, and his newest book, "Differ We Must: How Lincoln Succeeded in a Divided America," takes a long hard look at Lincoln the politician: the man who went out of his way to build political consensus, even with people whose views he considered noxious. It's a case for why we should collaborate, and yes, compromise with people across the aisle – not because it's nice or the right thing to do, but because it makes our government work.
Pragmatic politics focused on the public interest for those uncomfortable with America's two-party system and its way of doing politics. Considering the interface of politics with psychology, cognitive biology, social behavior, morality and history.
Etiquette
Tuesday, October 24, 2023
History bit: Abraham Lincoln's pragmatism & compromise
News bits: Drug company spending patterns; Global warming update; Etc.
Prescription drugs are a massive market: Americans spent $329.2 billion on prescription drugs in 2013. That works out to about $1,000 per person in the U.S., as John Oliver pointed out in his show on Sunday night. Oliver also mentioned that nine out of 10 big pharmaceutical companies spend more on marketing than on research.
Under fire for skyrocketing drug prices, pharmaceutical companies often offer this response: The high costs of their products are justified because the proceeds generate money for crucial research on new cures and treatments. It’s a compelling argument, but only partly true. As a revealing new academic study shows, big pharmaceutical companies have spent more on share buybacks and dividends in a recent 10-year period than they did on research and development.
The Israeli military has launched one of its most violent attacks on the Gaza Strip since its latest bombing campaign began two weeks ago, further devastating the occupied territory as its overwhelmed healthcare system and humanitarian services teeter on the brink of collapse.
Over just the past 24 hours, Israeli airstrikes have killed more than 400 people in Gaza, bringing the enclave’s total death toll since October 7 to more than 4,500. Israeli bombs reportedly hit Gaza’s largest refugee camp on Sunday, killing dozens.
Gaza’s Interior Ministry said Israel also struck “residential apartments in the town of Khan Younis and the Nuseirat refugee camp, both of which are south of the evacuation line,” The Associated Press reported.But according to The New York Times, the Biden administration is “not making a demand of Israel and still supports the ground invasion.”
On Sunday, U.S. President Joe Biden joined the leaders of Canada, France, Germany, Italy, and the United Kingdom in issuing a joint statement reiterating their “support for Israel and its right to defend itself” and calling for “adherence to international humanitarian law,” which Israel has been accused of violating repeatedly with its indiscriminate airstrikes and blockade.
The Western leaders’ joint statement said they are “committed to continue close diplomatic coordination, including with key partners in the region, to prevent the conflict from spreading, preserve stability in the Middle East, and work toward a political solution and durable peace,” but they did not call for a cease-fire.
Monday, October 23, 2023
Health news bits: Drug industry fights drug price negotiation; Drug industry fights low-cost drugs
In recent months, drug manufacturers and their allies have filed 10 lawsuits attacking one of the Inflation Reduction Act’s core health policy achievements: its plan for Medicare to negotiate drug prices. Applying to a select number of especially profitable drugs that have been on the market for at least nine or 13 years, negotiation is intended to arrive at a fair price — at least 25 percent less than the manufacturer’s price — based on the drug’s proven clinical benefits. Manufacturers set prices without meaningful constraint, and the Inflation Reduction Act’s negotiation, the first round of which will begin next year, is predicted to save Medicare $100 billion by 2031. Now, the pharmaceutical industry is attempting to achieve through the courts what it could not through the legislative process — maintaining unreasonably high brand-name drug prices at the expense of the American public.
At their core, the complaints argue that giving Medicare the power to negotiate infringes the rights of pharmaceutical manufacturers to sell prescription drugs at any price they set. Their arguments rely on the untenable premise that for-profit companies have a constitutionally protected right to receive taxpayer dollars. Even more alarmingly, they assert that the unmatched profitability of the pharmaceutical industry is itself a public good that should be judicially guarded at the expense of patients and taxpayers. Courts and the public must reject these claims.
First, the manufacturers argue that the plan violates the takings clause of the Fifth Amendment, which prohibits the government from taking private property without just compensation. Manufacturers may have a right to own and sell their drugs. However, they do not have a right to any particular level of Medicare reimbursement. Courts have agreed that private health-care entities can’t set their own payment rates, or expect to participate in voluntary programs such as Medicare without conditions.
Second, manufacturers claim a violation of the Fifth Amendment due process clause, which prohibits the deprivation of liberty or property without due process of law. Courts have recognized due process rights in the context of certain public benefits, such as social security for those with disabilities. But Medicare is not a benefit program for drug manufacturers. Rather, Medicare’s intended beneficiaries are the American people, many of whom cannot afford the cost of drugs at the rates manufacturers have set.
Why low-cost ketamine is still inaccessible to many with severe depression
Patients with treatment-resistant depression are missing out on potentially life-changing treatment with ketamine because systemic barriers in the public health system have made it unaffordable.
The researchers drew attention to the fact that it is now more than 20 years since the first indications that generic ketamine was effective, but public funding to support research and patient access has been slow, uncoordinated and underfunded. They also say there have been insufficient commercial incentives to conduct the research and development of generic ketamine, nor any schemes promoting public-private partnerships.
There is now a stark disparity in the accessibility and cost of ketamine-based depression treatments. The patented, intranasal s-enantiomeric ketamine formulation, Spravato, is priced at around $500 to $900 per dose, whereas generic ketamine stands at about $5 to 20 per dose. This high cost has led to Spravato being rejected for public reimbursement three times and thus it remains largely inaccessible for Australian patients.This narrative is not unique to ketamine, as the article foresees a similar fate for upcoming psychedelic-assisted psychotherapy treatments, which are on the verge of entering the mental health treatment arena. The article suggests that without systemic interventions, the cycle of underutilizing low-cost effective solutions is set to continue, leaving patients unable to access treatments while threatening to blow out health care costs.
In a world filled with angst, is there really any hope for mankind?
I just want to leave this thought out there:
I am not referencing any source or news outlet, I am only referencing my own internal thoughts.
Even up here in Canada, we are feeling the tension, but nothing like the tension that is exploding south of the border. When talking politics with friends and family back in the US, it seems to be ALL gloom and doom.
AND many believe we are at a inflection point. WWIII could erupt over the Israeli conflict. It could erupt over the Ukraine conflict. It could erupt if China invades Taiwan.
There is also a growing trend towards Nationalism. We all know about it in the US. There is a rising tide of that in Germany while Italy elected a far-right government. Ditto with places like Finland and Greece.
Then there is the growing and very real climate crisis. Almost forgotten in the political upheaval. Global emissions actually rose in 2022. I doubt they will have shrunk by the end of this year.
So, despair and angst now rule our collective psyche. Well, to be honest, not MY psyche, but we can't all be Snowflakes. But yes, it is happening. Around the dinner table, online discussions, everyday gatherings. Even here in Canada.
AND TO ME, THERE IS THE RUB! People, as they become more anxious, tend to want to protect their own. And become MORE bitter about who is responsible for our pending doom. It's all the Israeli's fault - or all Hama's fault, or all Iran's fault, or all Trump's fault, or all Russia's fault, or all the fault of those damn Christian extremists or damn Muslim extremists, or ............. it's ALL the fault of the media, particularly social media.
It is NEVER our own fault.
So, back to the original question: Is there ANY hope for mankind? I am asking not only in context of what is actually happening in the political arena, BUT in context of how we are responding to what is happening out there. Have we (not each one of us individually, but the universal "we") given up on mankind?
